Characterization of alphavirus infection receptors
Characterization of alphavirus infection receptors
批准号:
7990854
负责人:
WILLIAM B KLIMSTRA
金额:
$18.31万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2011-06-30
关键词:
AddressAerosolsAffectAffinityAlphavirusAlphavirus InfectionsAntiviral AgentsArbovirusesArthralgiaArthropod VectorsArthropodsB-LymphocytesBindingBiological WarfareBioterrorismBrainC-Type LectinsCategoriesCell CommunicationCell Culture TechniquesCell LineCell Surface ReceptorsCellsCharacteristicsClassificationCytoplasmDiseaseEncephalitisEvaluationEventExpression LibraryFeverGenomeGoalsGrowthHeparitin SulfateHumanIn VitroInfectionInfection preventionInterruptionLaminin ReceptorLicensingLinkMediatingMolecularMorbidity - disease rateMusMutationPharmaceutical PreparationsPlayProteinsPuromycinRaji CellRepliconResearchRetroviridaeRoleScreening procedureStructural ProteinSystemTimeVaccinesVenezuelan Equine Encephalitis VirusVirusVirus Diseasesalphavirus receptorcDNA Librarycombatdesignhuman diseasein vivomortalityneurovirulencenovelparticlepublic health relevancereceptorresearch studyvectorviral RNA
中文摘要
描述(由申请方提供):甲病毒是节肢动物介导的病毒,可引起人类疾病,范围从轻度发热性疾病到重度关节痛或致命性脑炎。由于几个因素,包括其易于分离、长期稳定性和通过气雾剂给药时高发病率/死亡率的可能性,几种已被指定为具有生物战/生物恐怖主义用途潜力的B类选择制剂。不幸的是,没有获得许可的疫苗或抗病毒药物可用于对抗这些感染。阻断病毒与细胞的初始相互作用是预防感染和疾病的最有效手段之一,了解病毒-感染受体相互作用对于设计感染阻断药物至关重要。然而,关于尚未广泛适应细胞培养生长的甲病毒的受体相互作用知之甚少。使用一种新的载体系统,我们建议同时检查,代表新世界和旧世界毒株的多种非细胞适应甲病毒的受体相互作用。在第一个目标中,我们将研究利用先前表征的细胞表面受体分子硫酸乙酰肝素和高亲和力层粘连蛋白受体,使用良好的表征细胞系。在第二个目标中,我们将利用我们的新型载体系统和最近在cDNA文库筛选中鉴定的甲病毒受体阴性细胞系来鉴定可以介导甲病毒感染细胞的新分子。这些实验的结果将提供对新世界和旧世界甲病毒受体相互作用的全面了解,并为设计感染阻断抗病毒药物提供框架。公共卫生相关性:我们的计划是使用一种新的嵌合甲病毒复制子系统,其中一个繁殖缺陷的委内瑞拉马脑炎病毒基因组被包装在不同的旧世界和新世界甲病毒的结构蛋白中,以比较这些病毒的低传代株的受体利用特征。这些比较将包括直接评价先前鉴定的受体(硫酸乙酰肝素,高亲和力层粘连蛋白受体)介导感染的能力,以及通过使用逆转录病毒表达文库和甲病毒受体阴性细胞表征新受体。
英文摘要
DESCRIPTION (provided by applicant): Alphaviruses are arthropod-vectored viruses that can cause human diseases ranging from mild febrile illness to severe arthralgia or fatal encephalitis. Due to several factors including the ease of their isolation, long-term stability and potential for high morbidity/mortality when administered by aerosol, several have been designated Category B Select Agents with potential for biowarfare/bioterrorism use. Unfortunately, no licensed vaccines or antiviral medications are available to combat these infections. Interruption of the initial interactions of viruses with cells is one of the most effective means of preventing infection and disease and an understanding of virus-infection receptor interactions is vital to design of infection-blocking drugs. However, little is known about the receptor interactions of alphaviruses that have not been adapted extensively to growth in cell culture. Using a novel vector system, we propose to examine simultaneously, the receptor interactions of multiple non-cell adapted alphaviruses representative of both New World and Old World strains. In the first Aim, we will investigate the utilization of previously characterized cell surface receptor molecules heparan sulfate and the high affinity laminin receptor using well-characterized cell lines. In the second Aim we will utilize our novel vector system and a recently-identified alphavirus receptor-negative cell line in a cDNA library screen to identify new molecules that can mediate alphavirus infection of cells. The results of these experiments will provide a comprehensive understanding of the receptor interactions of New World and Old World alphaviruses and provide a framework for design of infection-blocking antiviral drugs. PUBLIC HEALTH RELEVANCE: Our plan is to use a novel chimeric alphavirus replicon system in which a propagation-defective Venezuelan equine encephalitis virus genome is packaged in the structural proteins of different Old World and New World alphaviruses to compare the receptor utilization characteristics of low passage strains of these viruses. These comparisons will include direct evaluation of the capacity of previously-identified receptors (heparan sulfate, the high affinity laminin receptor) to mediate infection as well characterization of new receptors through use of a retrovirus expression library and alphavirus receptor-negative cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Viral and host factors in neuroinvasion of encephalitis alphaviruses
-
批准号:10659110
-
项目类别:
-
资助金额:$61.66万
-
财政年份:2022
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Viral and host factors in neuroinvasion of encephalitis alphaviruses
-
批准号:10389982
-
项目类别:
-
资助金额:$63.49万
-
财政年份:2022
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
-
批准号:10027464
-
项目类别:
-
资助金额:$47.22万
-
财政年份:2020
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
-
批准号:10405637
-
项目类别:
-
资助金额:$48.44万
-
财政年份:2020
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
-
批准号:10188419
-
项目类别:
-
资助金额:$47.77万
-
财政年份:2020
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
-
批准号:10674134
-
项目类别:
-
资助金额:$45.52万
-
财政年份:2020
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
-
批准号:10636632
-
项目类别:
-
资助金额:$48.66万
-
财政年份:2020
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Development of a novel live attenuated vaccine for eastern equine encephalitis virus
-
批准号:8869837
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2015
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Characterization of microRNA binding sites in the eastern equine encephalitis virus 3'NTR
-
批准号:8966629
-
项目类别:
-
资助金额:$22.47万
-
财政年份:2014
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Characterization of microRNA binding sites in the eastern equine encephalitis virus 3'NTR
-
批准号:8821225
-
项目类别:
-
资助金额:$18.72万
-
财政年份:2014
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular mechanisms of eastern equine encephalitis virus pathogenesis
-
批准号:9594677
-
项目类别:
-
资助金额:$48.52万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular mechanisms of eastern equine encephalitis virus pathogenesis
-
批准号:10177840
-
项目类别:
-
资助金额:$44.93万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular mechanisms of eastern equine encephalitis virus pathogenesis
-
批准号:10416025
-
项目类别:
-
资助金额:$48.55万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular Mechanisms of Eastern Equine Encephalitis Virus Pathogenesis
-
批准号:8792169
-
项目类别:
-
资助金额:$42.93万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular Mechanisms of Eastern Equine Encephalitis Virus Pathogenesis
-
批准号:8294295
-
项目类别:
-
资助金额:$44.21万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular Mechanisms of Eastern Equine Encephalitis Virus Pathogenesis
-
批准号:8608475
-
项目类别:
-
资助金额:$44.13万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular Mechanisms of Eastern Equine Encephalitis Virus Pathogenesis
-
批准号:8997056
-
项目类别:
-
资助金额:$42.93万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Molecular Mechanisms of Eastern Equine Encephalitis Virus Pathogenesis
-
批准号:8415824
-
项目类别:
-
资助金额:$40.35万
-
财政年份:2012
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
A Small Animal Model for Viscerotropic Disease to Improve Yellow Fever Vaccine
-
批准号:8868891
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2011
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
Efficacy of the antiviral state versus Sindbis and Venezuelan equine encephalitis
-
批准号:8312719
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2010
-
负责人:WILLIAM B KLIMSTRA
-
依托单位:
海外基金